EYEVENSYS

PulseSight Therapeutics is advancing an exciting pipeline of novel vectorized therapies designed to address still unmet need for treatments against severe retinal diseases leading to blindness, with a focus on age-related macular degeneration (AMD) including wet AMD and late stage dry AMD/Geographic atrophy (GA)... Our two programs, PST-611, in dry AMD/GA and PST-809, in wet AMD are at the very late stage of preclinical IND enabling studies, ready to enter clinical phase shortly. They build on over a decade of development of non-viral gene therapies including a Phase 1 study (in uveitis indication) demonstrating safety of PulseSight's approach 2. Our technology and its therapeutic applications are covered by a solid intellectual property portfolio of 11 patent families, with 90 granted patents... Our team includes seasoned and highly skilled professionals specialized in ophthalmology, gene therapy, and drug development, with an executive leadership team with proven track record..

Also known as: PULSESIGHT THERAPEUTICS

Primary location: Paris France